Aug 16, 2012 - Although the European Randomized Study of Screening for Prostate Cancer has reported a 29 percent reduction in prostate-cancer mortality for men who undergo prostate-specific antigen screening, the benefit is attenuated by loss of quality-adjusted life-years due to post-diagnosis effects, according to a study published in the Aug. 16 issue of the New England Journal of Medicine.